Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

Joseph Ciccolini, PhD
Published: Friday, Apr 21, 2017



Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

The dose of cetuximab must be precise otherwise it will be difficult for a patient with head and neck cancer to see results, explains Ciccolini.

It needs to be ensured that the drug is at a certain level to exert constant pressure on the target. This makes dose de-escalation difficult with this drug, but it was the best way to see responses, states Ciccolini.
 
SELECTED
LANGUAGE


Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

The dose of cetuximab must be precise otherwise it will be difficult for a patient with head and neck cancer to see results, explains Ciccolini.

It needs to be ensured that the drug is at a certain level to exert constant pressure on the target. This makes dose de-escalation difficult with this drug, but it was the best way to see responses, states Ciccolini.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x